Advertisement

Impact of Incorporating Trabecular Bone Score Into Fracture Risk Assessment and Recommendation for Use of Bone-Modifying Agents in Women With Breast Cancer

  • Mahwash F. Siddiqui
    Affiliations
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
  • Naim M. Maalouf
    Correspondence
    Address for correspondence: Naim M. Maalouf, MD, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas TX 75390-8885
    Affiliations
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

    Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
      We read with great interest the recent review article by Shapiro on the use of bone modifying agents (BMA) in patients with breast cancer.
      • Shapiro CL.
      Bone-modifying agents (BMAs) in breast cancer.
      The article highlights the importance of fracture risk assessment in guiding prevention and treatment of low bone mass in patients with breast cancer, and in determining the need to initiate BMAs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shapiro CL.
        Bone-modifying agents (BMAs) in breast cancer.
        Clin Breast Cancer. 2021; (Published online)https://doi.org/10.1016/j.clbc.2021.04.009
        • Gralow JR
        • Biermann JS
        • Farooki A
        • et al.
        NCCN task force report: bone health in cancer care.
        J Natl Compr Cancer Netw. 2013; 11: S-1-S-50https://doi.org/10.6004/jnccn.2013.0215
        • Hadji P
        • Aapro MS
        • Body JJ
        • et al.
        Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
        J Bone Oncol. 2017; 7: 1-12https://doi.org/10.1016/j.jbo.2017.03.001
        • Shapiro CL
        • Lacchetti C
        • Neuner J.
        Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline summary.
        J Oncol Pract. 2019; 15: 665-669https://doi.org/10.1200/JOP.19.00427
        • Coleman R
        • Hadji P
        • Body JJ
        • et al.
        Bone health in cancer: ESMO clinical practice guidelines.
        Ann Oncol. 2020; 31: 1650-1663https://doi.org/10.1016/j.annonc.2020.07.019
        • Martineau P
        • Leslie WD.
        Trabecular bone score (TBS): Method and applications.
        Bone. 2017; 104: 66-72https://doi.org/10.1016/j.bone.2017.01.035
        • McCloskey EV.
        • Odén A
        • Harvey NC
        • et al.
        A Meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX.
        J Bone Miner Res. 2016; 31: 940-948https://doi.org/10.1002/jbmr.2734
        • DeSantis CE
        • Ma J
        • Gaudet MM
        • et al.
        Breast cancer statistics.
        CA Cancer J Clin. 2019; 69: 438-451https://doi.org/10.3322/caac.21583